{
  "drugid": "RxNorm:3247",
  "drugname": "desipramine",
  "guidelinename": "CYP2D6, CYP2C19 and Tricyclic Antidepressants",
  "url": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/",
  "guidelinepharmgkbids": [
    "PA166104998",
    "PA166104999",
    "PA166105000",
    "PA166105001",
    "PA166105002",
    "PA166105006",
    "PA166105007"
  ],
  "citations": [
    {
      "pmid": "27997040",
      "title": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update",
      "authors": [
        "Kevin Hicks J",
        "Sangkuhl Katrin",
        "Swen Jesse J",
        "Ellingrod Vicki L",
        "Müller Daniel J",
        "Shimoda Kazutaka",
        "Bishop Jeffrey R",
        "Kharasch Evan D",
        "Skaar Todd C",
        "Gaedigk Andrea",
        "Dunnenberger Henry M",
        "Klein Teri E",
        "Caudle Kelly E",
        "Stingl Julia C"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2016
    },
    {
      "pmid": "23486447",
      "title": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants",
      "authors": [
        "Hicks J K",
        "Swen J J",
        "Thorn C F",
        "Sangkuhl K",
        "Kharasch E D",
        "Ellingrod V L",
        "Skaar T C",
        "Müller D J",
        "Gaedigk A",
        "Stingl J C"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2013
    }
  ],
  "recommendations": [
    {
      "implications": {
        "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."
      },
      "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Poor Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "0.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "0.0"
      },
      "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
      "population": "general",
      "genotypes": null,
      "source": "CPIC"
    },
    {
      "implications": {
        "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."
      },
      "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "0.25"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "0.25"
      },
      "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
      "population": "general",
      "genotypes": null,
      "source": "CPIC"
    },
    {
      "implications": {
        "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."
      },
      "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "0.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "0.5"
      },
      "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
      "population": "general",
      "genotypes": null,
      "source": "CPIC"
    },
    {
      "implications": {
        "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."
      },
      "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "0.75"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "0.75"
      },
      "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
      "population": "general",
      "genotypes": null,
      "source": "CPIC"
    },
    {
      "implications": {
        "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."
      },
      "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "1.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "1.0"
      },
      "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
      "population": "general",
      "genotypes": null,
      "source": "CPIC"
    },
    {
      "implications": {
        "CYP2D6": "Normal metabolism of TCAs"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "1.25"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "1.25"
      },
      "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
      "population": "general",
      "genotypes": null,
      "source": "CPIC"
    },
    {
      "implications": {
        "CYP2D6": "Normal metabolism of TCAs"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "1.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "1.5"
      },
      "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
      "population": "general",
      "genotypes": null,
      "source": "CPIC"
    },
    {
      "implications": {
        "CYP2D6": "Normal metabolism of TCAs"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "1.75"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "1.75"
      },
      "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
      "population": "general",
      "genotypes": null,
      "source": "CPIC"
    },
    {
      "implications": {
        "CYP2D6": "Normal metabolism of TCAs"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "2.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "2.0"
      },
      "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
      "population": "general",
      "genotypes": null,
      "source": "CPIC"
    },
    {
      "implications": {
        "CYP2D6": "Normal metabolism of TCAs"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "2.25"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "2.25"
      },
      "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
      "population": "general",
      "genotypes": null,
      "source": "CPIC"
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
      },
      "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "2.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "2.5"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null,
      "source": "CPIC"
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
      },
      "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "≥3.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "≥3.0"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null,
      "source": "CPIC"
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
      },
      "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "3.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "3.0"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null,
      "source": "CPIC"
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
      },
      "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "≥3.25"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "≥3.25"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null,
      "source": "CPIC"
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
      },
      "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "≥3.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "≥3.5"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null,
      "source": "CPIC"
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
      },
      "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "3.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "3.5"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null,
      "source": "CPIC"
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
      },
      "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "≥4.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "≥4.0"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null,
      "source": "CPIC"
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
      },
      "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "4.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "4.0"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null,
      "source": "CPIC"
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
      },
      "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "≥4.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "≥4.5"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null,
      "source": "CPIC"
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
      },
      "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "≥5.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "≥5.0"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null,
      "source": "CPIC"
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
      },
      "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "≥6.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "≥6.0"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null,
      "source": "CPIC"
    },
    {
      "implications": {
        "CYP2D6": "n/a"
      },
      "drugrecommendation": "No recommendation",
      "classification": "No Recommendation",
      "phenotypes": {
        "CYP2D6": "Indeterminate"
      },
      "activityscore": {
        "CYP2D6": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "n/a"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null,
      "source": "CPIC"
    }
  ],
  "genes": [
    "CYP2D6"
  ],
  "notesonusage": null,
  "cpicVersion": "v1.20.0-1-g4e458f4",
  "source": "CPIC"
}